Abstract: Compositions of, methods of making, and methods of using alkaline earth phosphate bone cements are disclosed. A bone cement composition includes a powder comprising a basic source of calcium, magnesium, or strontium, a setting solution comprising H3PO4 and a buffer, and a biocompatible polymer that is incorporated into the setting solution. The powder is mixed with the setting solution to form a bone cement paste that either (a) sets into a hardened mass, or (b) is irradiated with electromagnetic radiation to form dry powders, the dry powders then being mixed with a second setting solution to form a radiation-assisted bone cement paste that sets into a hardened mass.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
July 9, 2019
Assignee:
The University of Toledo
Inventors:
Sarit B. Bhaduri, Huan Zhou, Anand K. Agarwal, Vijay K. Goel
Abstract: Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
July 2, 2019
Assignee:
PROSIDYAN, INC.
Inventors:
Charanpreet S. Bagga, Steve B. Jung, Hyun W. Bae
Abstract: The present disclosure relates to new UV-filters, method of producing the same and their use in compositions in particular, cosmetic/pharmaceutical or textile compositions, namely sunscreens cream or sunscreens textile article, in particular the present disclosure relates to hydroxyapatite based-compound comprising Ca9FeH(PO4)7 and/or ?-Fe2O3 in hematite form for use in a method for protecting the skin against UV radiation.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
June 11, 2019
Assignee:
UNIVERSIDADE CATOLICA PORTUGUESA
Inventors:
Maria Manuela Estevez Pintado, Paula Castro, Clara Piccirillo
Abstract: An object of the present application is to provide an orally-disintegrating tablet having excellent tablet hardness and disintegrability, and including a disintegrative particulate composition. This invention relates to a disintegrative particulate composition comprising the four components consisting of a first disintegrator component of an acid-type carboxymethylcellulose, a second disintegrator component other than the acid-type carboxymethylcellulose, an excipient of a sugar or sugar alcohol, and crystalline cellulose; and to an orally-disintegrating tablet, including the disintegrative particulate composition and a medicinal ingredient.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
May 21, 2019
Assignees:
DAICEL CORPORATION, NICHIRIN CHEMICAL INDUSTRIES, LTD.
Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.
Abstract: The present invention provides methods for treating an inflammatory brain disease and for treating a traumatic brain injury in a human having an inflammatory component applying transdermal pharmaceutical compositions comprising chromium, magnesium, and thiamine as active ingredient compounds that act as neuroprotective iron chelators and brain glucose-uptake enhancement that are suitable for the treatment of traumatic brain injury. The invention further relates to methods of delivering the pharmaceutical compositions that target the brain and/or central nervous system certain novel iron chelators of the type described in the specification.
Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.
Type:
Grant
Filed:
September 5, 2011
Date of Patent:
April 9, 2019
Assignee:
EMPLICURE AB
Inventors:
Håkan Engqvist, Susanne Bredenberg, Anders Pettersson, Thomas Lundqvist, Anna Dahlgren, Anders Sågström
Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.
Type:
Grant
Filed:
July 27, 2012
Date of Patent:
February 12, 2019
Assignee:
GRUENENTHAL GMBH
Inventors:
Sebastian Schwier, Marcel Haupts, Lutz Barnscheid, Jana Pätz
Abstract: One aspect of the present invention relates to a multicomponent and biocompatible nanocomposite material, including a graphene structure formed with a plurality of graphene layers; and gold/hydroxyapatite (Au/HA) nanoparticles distributed within the graphene structure; where the nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD).
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
February 5, 2019
Assignee:
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Abstract: Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin.
Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of (a) providing a feedstock comprising an organic material(s) in a solvent system containing a non-solvent for the organic material at an elevated temperature and/or pressure above ambient conditions, (b) distributing the feedstock into either droplets or a film, and (d) evaporating the solvent system from the feedstock.
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, which alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.
Abstract: The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption.
Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D (v,0.9) is between 50 and 1 10 micrometers.
Abstract: The present invention provides a device for administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as an oral dissolving film formed therefore.
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, which alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.
Abstract: The present invention teaches an absorbent material with powdered activated carbon which is substantially light-colored without using color masking agents or hiding. This invention addresses the need in the field for an absorbent material with improved odor-controlling properties, that maintains such properties for longer periods of time and where the absorbent material maintains a light-colored appearance without the addition of color-masking agents. Suitable methods for creating the absorbent materials include a pan agglomeration process, a high shear agglomeration process, a low shear agglomeration process, a high pressure agglomeration process, a low pressure agglomeration process, a rotary drum agglomeration process, a pan agglomeration process, a roll press compaction process, a pin mixer process, a dry blending process, a spray coating process, an extrusion process, a pelletizing process and a fluid bed process.
Abstract: Compositions of, methods of making, and methods of using alkaline earth phosphate bone cements are disclosed. A bone cement composition includes a powder comprising a basic source of calcium, magnesium, or strontium, a setting solution comprising H3PO4 and a buffer, and a biocompatible polymer that is incorporated into the setting solution. The powder is mixed with the setting solution to form a bone cement paste that either (a) sets into a hardened mass, or (b) is irradiated with electromagnetic radiation to form dry powders, the dry powders then being mixed with a second setting solution to form a radiation-assisted bone cement paste that sets into a hardened mass.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
September 4, 2018
Assignee:
The University of Toledo
Inventors:
Sarit B. Bhaduri, Huan Zhou, Anand K. Agarwal, Vijay K. Goel
Abstract: The present disclosure provides a preparation method of rumen protected glucose, comprising the following steps: (1) preparing glucose into a pellet and drying; (2) fluidizing the pellet in a fluidized bed after drying; and (3) coating melted aliphatic alcohol and/or saturated fatty acid onto the surface of the pellet located in the fluidized bed to obtain a rumen protected bypass glucose particle. The prepared rumen-protected glucose could go through the rumen of ruminant effectively; and the availability of coating layer in ruminant increases, making the coated glucose be released completely and fully utilized by ruminant, so ketosis or subclinical ketosis and fatty liver disease of the ruminants in perinatal stage could be prevented and reduced effectively, the postpartum weight loss could be reduced, and the cycle conception rate and the milk yield could be increased.